Skip to main navigation

Home
Development Programs
VX15 Immuno-Oncology
VX15 Neurology
VX18 Neurology
VX15 Autoimmune
NKT Vaccine
NKT Vaccine
ActivMAb^®
Vaccinia Display
Capabilities
Optimization
Target Identification
Publications
News & Publications
- News
- Publications
Careers
Corporate
Investors
Main navigation
Events
Presentations

Home
About
Corporate Overview
Management
Partners
Pipeline
Pepinemab
Neurology
Pepinemab
Immuno-Oncology
Research & Development Programs
Clinical Trials
Patients
Physicians & Researchers
News & Publications
- News
- Publications
Investors
Main navigation
Events
Presentations
Careers
Contact Us
ActivMAb ^®

Science in the service of medicine

About
Pipeline
Clinical Trials
- Patients
- Physicians & Researchers

News & Publications
- News
- Publications
Investors
Main navigation
Events
Presentations
Careers
Contact Us
ActivMAb ^®

News Releases

News Releases

Investors

Investor Overview
News Releases
Events
Presentations
Stock Information
Corporate Governance
Financial Information
Investor Services

Shareholder Tools

Print Page
RSS Feeds
E-mail Alerts
IR Contacts
LinkedIn
Twitter

News Releases

Keyword Search

Year

09/17/21

Vaccinex to Present at the Oppenheimer & Co. Inc. Fall Healthcare Life Sciences and MedTech Summit

09/15/21

Vaccinex CEO, Dr. Maurice Zauderer, Presented New and Promising Phase 2 SIGNAL Trial Data in a Plenary Session at the European Huntington’s Disease Network Meeting

08/16/21

Vaccinex Reports Second Quarter 2021 Financial Results and Provides Corporate Update

06/30/21

Vaccinex to Chair Panel Q&A Session and Present Poster at the XV European Meeting on Glial Cells in Health and Disease

06/08/21

Vaccinex Announces Activation of Clinical Sites to Enroll Patients in Studies of Pepinemab as Single Agent in Alzheimer’s Disease and in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

05/19/21

Vaccinex to Present at the Jefferies 2021 Virtual Healthcare Conference

05/17/21

Vaccinex Reports First Quarter 2021 Financial Results and Provides Corporate Update

04/21/21

Vaccinex Announces Publication of Results from CLASSICAL-Lung Phase 1b/2 Clinical Trial in Non-Small Cell Lung Cancer in the Peer-Reviewed Journal Clinical Cancer Research

03/16/21

Vaccinex Reports Fourth Quarter 2020 Financial Results and Provides Corporate Update

03/11/21

Vaccinex to Present at the Oppenheimer 31st Annual Healthcare Conference

02/22/21

Vaccinex Announces Licensing of Anti-CCR8 Antibody to Surface Oncology

02/19/21

Vaccinex Announces Signing of Two Multi-Project Deals with Leading Pharmaceutical Companies Focused on Leveraging Its ActivMAb® Platform

01/05/21

Vaccinex to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event

About
Pipeline
Clinical Trials

News
Careers
Contact

Vaccinex Inc.
1895 Mount Hope Avenue, Rochester, NY 14620
P: 585-271-2700
F: 585-271-2765
info@vaccinex.com

© 2021 Vaccinex. All rights reserved
Privacy Policy
Site by Minerva